Treatment Options for Squamous NSCLC After Immunotherapy

In this segment, the panel discusses treatment considerations for patients with advanced squamous non-small cell lung cancer (NSCLC) who have progressed following immunotherapy and platinum-based chemotherapy but do not want additional chemotherapy. Dr. Narjust Florez emphasizes that there is currently no established chemotherapy-free regimen supported by phase 3 data for this setting and discusses clinical trials and best supportive care as available options. The experts also consider how clinical trial availability can vary, particularly in community settings, and the potential role of local therapy for symptom management while patients pursue additional treatment options. For patients who remain interested in treatment but are concerned about chemotherapy-related toxicities, the panel discusses factors such as baseline neuropathy, bone marrow suppression, alopecia, and the burden of frequent infusions. Single-agent chemotherapy may be considered in selected patients, although the panel notes the limitations of response and durability. The discussion also highlights the potential role of local therapy for symptom control in patients with centrally located squamous tumors and the importance of clearly communicating realistic treatment expectations.